Clinical Trial Update: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SOM230 (pasireotide) in patients with pituitary Cushing's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing's Syndrome | Phase 2 | Status: COMPLETED